Compare ARI & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | PRCT |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2009 | 2021 |
| Metric | ARI | PRCT |
|---|---|---|
| Price | $11.06 | $24.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $11.00 | ★ $35.44 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | ★ 183.51 | 1.71 |
| EPS | ★ 0.81 | N/A |
| Revenue | $271,589,000.00 | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | N/A | $24.52 |
| P/E Ratio | $13.86 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $8.09 | $19.35 |
| 52 Week High | $11.24 | $64.89 |
| Indicator | ARI | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.31 | 47.37 |
| Support Level | $9.59 | $19.35 |
| Resistance Level | $11.12 | $28.07 |
| Average True Range (ATR) | 0.19 | 1.39 |
| MACD | 0.06 | 0.13 |
| Stochastic Oscillator | 78.11 | 41.69 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.